See more : Annovis Bio, Inc. (ANVS) Income Statement Analysis – Financial Results
Complete financial analysis of Nascent Biotech, Inc. (NBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nascent Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- President Energy Plc (PPC.L) Income Statement Analysis – Financial Results
- Decklar Resources Inc. (DKL.V) Income Statement Analysis – Financial Results
- Gelion plc (GELNF) Income Statement Analysis – Financial Results
- NXT Energy Solutions Inc. (NSFDF) Income Statement Analysis – Financial Results
- Haydale Graphene Industries plc (HAYD.L) Income Statement Analysis – Financial Results
Nascent Biotech, Inc. (NBIO)
About Nascent Biotech, Inc.
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.00M | 750.00K | 0.00 | 0.00 | 0.00 | 3.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 319.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -319.51K | 0.00 | 1.00M | 750.00K | 0.00 | 0.00 | 0.00 | 3.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 203.44K | 270.53K | 197.41K | 321.94K | 293.71K | 254.01K | 1.19M | 486.93K | 1.15M | 1.67M | 383.72K | 381.27K |
| General & Administrative | 1.71M | 1.49M | 927.36K | 1.83M | 3.15M | 1.11M | 1.03M | 1.57M | 4.29M | 469.84K | 186.60K | 291.98K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.71M | 1.49M | 927.36K | 1.83M | 3.15M | 1.11M | 1.03M | 1.57M | 4.29M | 469.84K | 186.60K | 291.98K |
| Other Expenses | 0.00 | 1.50M | 332.29K | -369.00 | 0.00 | 0.00 | 0.00 | -479.65K | -1.57M | -20.00K | 1.34M | 0.00 |
| Operating Expenses | 2.23M | 2.14M | 1.46M | 2.15M | 3.45M | 1.37M | 2.22M | 1.57M | 5.44M | 2.13M | 1.91M | 674.31K |
| Cost & Expenses | 2.23M | 2.14M | 1.46M | 2.15M | 3.45M | 1.37M | 2.22M | 1.57M | 5.44M | 2.13M | 1.91M | 674.31K |
| Interest Income | 0.00 | 274.00 | 12.00 | 5.00 | 6.00 | 41.00 | 125.00 | 141.00 | 0.00 | 0.00 | 0.00 | 14.79K |
| Interest Expense | 379.97K | 1.72M | 336.02K | 336.63K | 86.63K | 0.00 | 0.00 | 54.13K | 280.50K | 24.00K | 11.94K | 0.00 |
| Depreciation & Amortization | 2.23M | 2.16M | 457.05K | 1.40M | 3.45M | 1.37M | 2.22M | -947.77K | 5.44M | 1.09K | 1.09K | 1.06K |
| EBITDA | 527.43K | 0.00 | -134.41K | 0.00 | -470.21K | 41.00 | 471.00 | 1.43M | 0.00 | -2.14M | -570.31K | -625.10K |
| EBITDA Ratio | 0.00% | 0.00% | -60.82% | -189.35% | 0.00% | 0.00% | 0.00% | 47.59% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.23M | -2.16M | -457.05K | -1.40M | -3.45M | -1.37M | -2.22M | 1.43M | -5.44M | -2.14M | -571.40K | -674.31K |
| Operating Income Ratio | 0.00% | 0.00% | -45.71% | -186.72% | 0.00% | 0.00% | 0.00% | 47.58% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 142.20K | -645.21K | -13.34K | 441.60K | -556.84K | 41.00 | 471.00 | -50.49K | 1.30M | -29.05K | -1.30M | 33.36K |
| Income Before Tax | -2.09M | -2.80M | -470.39K | -958.77K | -4.00M | -1.37M | -2.22M | 1.38M | -4.15M | -2.15M | -1.92M | -689.11K |
| Income Before Tax Ratio | 0.00% | 0.00% | -47.04% | -127.84% | 0.00% | 0.00% | 0.00% | 45.90% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.21M | -322.69K | 356.04K | 86.63K | -41.00 | -471.00 | 240.00K | -499.00 | 6.00K | 20.00K | 30.00K |
| Net Income | -2.09M | -2.80M | -147.71K | -1.31M | -4.09M | -1.37M | -2.22M | 1.14M | -4.15M | -2.15M | -1.92M | -689.11K |
| Net Income Ratio | 0.00% | 0.00% | -14.77% | -175.31% | 0.00% | 0.00% | 0.00% | 37.90% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.01 | -0.02 | 0.00 | -0.02 | -0.12 | -0.05 | -0.09 | 0.05 | -0.21 | -0.15 | -0.61 | -0.26 |
| EPS Diluted | -0.01 | -0.02 | 0.00 | -0.02 | -0.12 | -0.05 | -0.09 | 0.05 | -0.21 | -0.15 | -0.61 | -0.26 |
| Weighted Avg Shares Out | 155.75M | 118.57M | 107.74M | 72.34M | 34.39M | 30.09M | 25.88M | 21.80M | 19.77M | 13.99M | 3.15M | 2.69M |
| Weighted Avg Shares Out (Dil) | 155.74M | 118.57M | 107.74M | 72.34M | 34.39M | 30.09M | 25.88M | 21.80M | 19.77M | 13.99M | 3.15M | 2.69M |
Nascent Biotech Presents at the July Emerging Growth Conference
Nascent CEO-Sean Carrick-Discusses Phase I Results and Forward Clinical Strategy while laying out Investment Opportunity of the Company NORTH PALM BEACH, FL / ACCESSWIRE / July 30, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"),...
Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
NORTH PALM BEACH, FL / ACCESSWIRE / April 16, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, announces that it is embarking on a fresh...
Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System
NORTH PALM BEACH, FL / ACCESSWIRE / March 19, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, and HypoSpray Pharma ("HypoSpray®"), a clinical and commercial...
Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates
NORTH PALM BEACH, FL and NEW YORK, NY / ACCESSWIRE / February 6, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies for the treatment of various cancers and viral...
Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued
Analysts suggest Nascent Value at $0.60 to $2.84 per share NORTH PALM BEACH, FL / ACCESSWIRE / January 9, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies focused on...
Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk
NORTH PALM BEACH, FL / ACCESSWIRE / December 19, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers, is pleased to announce...
Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier
NORTH PALM BEACH, FL / ACCESSWIRE / November 29, 2023 / Nascent Biotech, Inc. (OTC:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is...
Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer
NORTH PALM BEACH, FL / ACCESSWIRE / August 22, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in the therapeutic monoclonal antibody space, announced today that the Company...
Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting
NORTH PALM BEACH, FL / ACCESSWIRE / May 9, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in therapeutic monoclonal antibody space, announced today that the Company has...
Nascent Biotech and Manhattan BioSolutions Announce Promising Prelim/Preclinical Results in BCG-Based COVID-19 Vaccine Research Collaboration
SAN DIEGO, CA / ACCESSWIRE / July 13, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a biotechnology company pioneering innovative medicines to overcome difficult-to-treat cancers and viral infections, and its collaboration partner, Manhattan BioSolutions (together,...
Source: https://incomestatements.info
Category: Stock Reports